Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
April 19, 2004
- Switching from Dependent to Independent Management at Nat'l Hospitals: Dr Yazaki
April 19, 2004
- 124th Annual Meeting of the Pharmaceutical Society of Japan
April 19, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
April 19, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
April 19, 2004
- 1st 3Qtrs Business Results
April 19, 2004
- DIAGNOSTIC NEWS IN BRIEF
April 19, 2004
- JPA Submits Petition on Drug Marketing to Dr Sakaguchi
April 19, 2004
- 218 Development Programs Underway in US: Dr Feczko of Pfizer
April 19, 2004
- Nearly 50% Would Purchase Regular OTC Drugs from Convenience Stores: JSMI Survey
April 19, 2004
- We Can Become the World's Top Company: Dr Patterson of AstraZeneca
April 19, 2004
- OTC NEWS IN BRIEF
April 19, 2004
- Gov't Approves 3-Year Plan for Regulatory Reform
April 12, 2004
- Medical Institutions Should Disclose Accidents: Dr Sakaguchi
April 12, 2004
- Dr Sakaguchi Sees Domestic, Foreign Drug Price Gap as "Major Problem"
April 12, 2004
- Insurance Coverage Requested for Candesartan as CHF Treatment
April 12, 2004
- REGULATORY NEWS IN BRIEF
April 12, 2004
- Sales of Bayer HealthCare in Japan Level Last Year: Dr Portoff
April 12, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 12, 2004
- MEDICAL DEVICE NEWS IN BRIEF
April 12, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…